2K3 Stock Overview
A medical device company, focuses on solving musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. More details
Snowflake Score | |
---|---|
Valuation | 1/6 |
Future Growth | 1/6 |
Past Performance | 0/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
Rewards
Risk Analysis
Community vs My Fair Value
Select a narrative for quick price alerts from the community, or create your own.
SI-BONE, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$11.00 |
52 Week High | US$17.20 |
52 Week Low | US$10.60 |
Beta | 0.82 |
1 Month Change | -3.51% |
3 Month Change | n/a |
1 Year Change | -20.29% |
3 Year Change | -32.10% |
5 Year Change | -28.10% |
Change since IPO | -34.29% |
Recent News & Updates
Recent updates
Shareholder Returns
2K3 | DE Medical Equipment | DE Market | |
---|---|---|---|
7D | 0% | 4.7% | 0.8% |
1Y | -20.3% | -8.9% | 14.6% |
Return vs Industry: 2K3 underperformed the German Medical Equipment industry which returned -12.1% over the past year.
Return vs Market: 2K3 underperformed the German Market which returned 14% over the past year.
Price Volatility
2K3 volatility | |
---|---|
2K3 Average Weekly Movement | 12.8% |
Medical Equipment Industry Average Movement | 6.3% |
Market Average Movement | 6.5% |
10% most volatile stocks in DE Market | 12.9% |
10% least volatile stocks in DE Market | 3.1% |
Stable Share Price: 2K3's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 2K3's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2008 | 349 | Laura Francis | si-bone.com |
SI-BONE, Inc., a medical device company, focuses on solving musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. The company offers proprietary minimally invasive surgical implant systems to address sacroiliac joint dysfunction and degeneration, adult deformity and degeneration, and pelvic trauma, as well as implantable bone products. It also provides iFuse-3D, a titanium implant that combines the triangular cross-section of the iFuse implant with a proprietary 3D-printed porous surface and fenestrated design; iFuse TORQ, a line of 3D-printed threaded implants designed for applications in pelvic trauma and sacroliliac fusion; and iFuse Bedrock Granite Implant System that provides sacroiliac fusion and sacropelvic fixation as a foundational element for segmental spinal fusion; and iFuse TORQ TNT to treat pelvic trauma and sacroiliac joint dysfunction, as well as iFuse INTRA implants that are marketed as human cells, tissues, and cellular or tissue-based products.
SI-BONE, Inc. Fundamentals Summary
2K3 fundamental statistics | |
---|---|
Market cap | €756.39m |
Earnings (TTM) | -€23.81m |
Revenue (TTM) | €158.39m |
4.8x
P/S Ratio-31.8x
P/E RatioIs 2K3 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
2K3 income statement (TTM) | |
---|---|
Revenue | US$176.60m |
Cost of Revenue | US$36.65m |
Gross Profit | US$139.95m |
Other Expenses | US$166.50m |
Earnings | -US$26.55m |
Last Reported Earnings
Mar 31, 2025
Next Earnings Date
n/a
Earnings per share (EPS) | -0.62 |
Gross Margin | 79.25% |
Net Profit Margin | -15.03% |
Debt/Equity Ratio | 21.2% |
How did 2K3 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2025/05/17 16:53 |
End of Day Share Price | 2025/05/05 00:00 |
Earnings | 2025/03/31 |
Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
SI-BONE, Inc. is covered by 13 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
Craig Bijou | BofA Global Research |
Caitlin Cronin | Canaccord Genuity |
Ross Osborn | Cantor Fitzgerald & Co. |